Executives from Trupanion (NASDAQ:TRUP) outlined their outlook for 2026, discussed evolving customer acquisition strategy, and addressed capital allocation priorities during a conference fireside chat featuring President and CEO Margi Tooth and Chief Financial Officer Fawwad Qureshi.
2026 outlook: pricing still leads, with growing role for headcount
Qureshi said the company was “super happy” with its 2025 results and is focused on continuing that momentum in 2026. He told investors that pricing is expected to remain the larger contributor to revenue growth in 2026, though less so than in 2025, with a “gradual shift” toward headcount contributing more meaningfully than it did last year. Even with that shift, he characterized 2026 as “still a pricing-led year.”
Qureshi said the company intends to keep investing in technology—describing it as a differentiator—and cited claims automation as an example. He said those investments are being funded through efficiencies across the expense base, and he expects continued adjusted operating margin expansion by year-end.
Go-to-market: reinforcing vet channel while broadening top-of-funnel demand
Tooth described Trupanion’s distribution strategy as centered on the veterinary channel, calling it a focal point of “every conversation” once a pet reaches the vet. She also highlighted efforts with breeders and shelters, emphasizing a focus on “all stages of early pet ownership and adoption.”
She said the company has increased spending to rebuild the “framework” needed for growth after pulling back on pet acquisition spend in prior years. That includes brand presence in hospitals and efforts to increase awareness among breeders and pet parents.
Tooth said Trupanion is working to reach pet parents earlier in the funnel—where they shop, browse, and seek education—using Trupanion’s data to place the brand “into the eyes and minds” of prospective customers. She characterized the approach as complementary to veterinarian-driven acquisition, aiming to make the vet conversation faster and easier when pet owners are already familiar with the brand.
Category growth and Trupanion’s growth posture
Asked about category growth and Trupanion’s position relative to peers, Tooth said industry penetration is around 4% to 4.5%, while noting that 2025 industry figures had not yet been released. She said rising veterinary costs are pushing consumers toward “more solutions,” including insurance.
Tooth reiterated that Trupanion has been deliberate about “getting the price right” and maintaining retention before leaning into aggressive growth. She acknowledged that some competitors may have been growing faster because they had different priorities, but said the market remains “greenfield” and focused on building awareness and education rather than taking share from incumbents.
She said Trupanion is not pursuing “growth at all costs,” emphasizing value and margin per pet. Tooth also pointed to the company’s confidence after achieving what she described as a “level set” margin for the full year in 2025 for the first time in company history, positioning Trupanion to become more aggressive over a three- to five-year horizon.
Affordability, product communication, and potential new offerings
In a discussion about affordability and consumer “sticker shock,” Tooth pushed back on the premise that Trupanion is the most expensive product, saying it is “actually the least expensive product over the line,” and argued that consumers may not understand key differences across providers. She highlighted Trupanion’s practice of locking in an enrolled pet’s age as part of its value proposition.
Tooth said Trupanion is considering how to evolve offerings for pet parents who cannot afford a comprehensive product. She suggested the company could develop a less comprehensive product with different features and limits while retaining elements such as direct pay and the Trupanion brand promise that veterinarians recognize.
Tooth also addressed two lower-value products launched in Canada—PHI Direct and Furkin—saying they remain in Canada and continue operating, but Trupanion reduced investment in them during a period of margin compression as it prioritized higher lifetime value acquisition. She said the company has learned from those products and now believes its brand equity and expanded hospital footprint could help support a broader portfolio under the Trupanion umbrella, rather than funding separate brands independently.
Free cash flow, investment capacity, and holder-base update
Qureshi said Trupanion generated approximately 5% free cash flow as a percentage of revenue in 2025, above a stated goal of at least 2.5%. He attributed roughly two-thirds of free cash flow generation to adjusted operating income (AOI) rather than broad expense reduction, and said stronger free cash flow improves optionality—supporting marketing and pet acquisition spend, technology investment (including automation and member experience tools), and financial actions such as debt paydown. He said the company paid down about $17.5 million in 2025.
Discussing a separate growth initiative, Qureshi said the company views its “LabSpec” opportunity as early stage and did not provide a specific market profile, but argued the pet food business could ultimately have a superior market profile to pet insurance due to proprietary IP and distribution through veterinary channels. He said the business will take time to scale but could eventually be as large as, or larger than, pet insurance with more favorable economics.
On recent 13F-related investor questions, management said a large holder’s reported exit reflected a transfer: a director moved holdings from Tarmac to a related entity, Felix Holding, and management added that the position had increased.
In closing comments, Tooth said the company intends to be “aggressive from a pet count point of view” and highlighted the company’s use of AI tools to improve operational efficiency and member experience. She said those technology efforts support better leverage and a more personalized customer experience, adding that Trupanion enters the year in what she described as an “incredibly strong financial position.”
About Trupanion (NASDAQ:TRUP)
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
